Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsGregor Gryglewski, MD, PhD
Assistant Professor Adjunct in the Child Study CenterAbout
Research
Publications
2026
Acute effects of selective serotonin reuptake inhibitors on cerebral glucose metabolism and blood flow
Silberbauer L, Reed M, Gryglewski G, Murgaš M, Nics L, Godbersen G, Stimpfl T, Hahn A, Hacker M, Lanzenberger R. Acute effects of selective serotonin reuptake inhibitors on cerebral glucose metabolism and blood flow. Translational Psychiatry 2026, 16: 54. PMID: 41633980, PMCID: PMC12873367, DOI: 10.1038/s41398-026-03849-2.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsSerotonin transporterPseudo-continuous arterial spin labelingAcute pharmacological effectsDorsal raphe nucleusAcute effectsBOLD signal changesBOLD fMRI studiesCerebral glucose metabolismFunctional positron emission tomographyFMRI studyPsychopharmacological researchRaphe nucleusSerotonergic projectionsNeuropsychiatric disordersBrain activityOccipital cortexNeuroimaging protocolsPositron emission tomographyDouble-blind study designNeuronal activityPlacebo-ControlledBrain energy demand
2025
Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis
Silberbauer L, Eggerstorfer B, Michenthaler P, Reichel S, Stimpfl T, Vanicek T, Naderi-Heiden A, Kasper S, Lanzenberger R, Gryglewski G. Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis. Journal Of Affective Disorders 2025, 394: 120466. PMID: 41101490, DOI: 10.1016/j.jad.2025.120466.Peer-Reviewed Original ResearchConceptsKetamine treatmentPrimary endpointRandomized Controlled TrialsSevere depressive episodeSpecialized centersExposure to ketamineMeta-analysis of randomized controlled trialsAntidepressant efficacyAntidepressant treatmentAntidepressant therapyDepressive episodeDouble-blind trialOutcomes of patientsBipolar disorderForty-five patientsMeta-analysisEvidence up-to-dateOral ketamineWell-toleratedScore reductionAdverse eventsKetamineActive comparatorMidazolam solutionOral applicationPhenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder
Zadka Ł, Eggerstorfer B, Buzalewicz I, Vraka C, Rusak A, Godbersen G, Opalińska A, Unterholzner J, Ulatowska-Jarża A, Philippe C, Haczkiewicz-Leśniak K, Silberbauer L, Murgaš M, Nics L, Hahn A, Hacker M, Gomułkiewicz A, Rujescu D, Podhorska-Okołów M, Lanzenberger R, Gryglewski G. Phenotyping extracellular vesicles and their serotonin transporter cargo in major depressive disorder. Journal Of Affective Disorders 2025, 389: 119740. PMID: 40550277, DOI: 10.1016/j.jad.2025.119740.Peer-Reviewed Original ResearchSerotonin transporterDepressive disorderPresence of serotonin transporterAntidepressant treatment responseSerotonin transporter levelsMDD patientsNanoparticle tracking analysisMood disordersPsychiatric disordersMDDBinding potentialExtracellular vesiclesTreatment response predictionPositron emission tomographyTreatment responseDisordersHealthy controlsExosome markers CD63Blood-brain barrierEmission tomographyStudy intercellular communicationPrognostic valueConcentration of extracellular vesiclesPatient stratificationExosomal markersA large-scale multimodal investigation of the interplay between the serotonergic system and emotion processing
Klöbl M, Murgaš M, Reed M, Silberbauer L, Hartmann A, Godbersen G, Gryglewski G, Nics L, Hahn A, Rujescu D, Hacker M, Lanzenberger R. A large-scale multimodal investigation of the interplay between the serotonergic system and emotion processing. Translational Psychiatry 2025, 15: 196. PMID: 40500269, PMCID: PMC12159172, DOI: 10.1038/s41398-025-03407-2.Peer-Reviewed Original ResearchConceptsAnterior cingulate cortex activationAnterior cingulate cortexMajor depressive disorderFunctional magnetic resonance imagingSerotonin transporter availabilitySerotonin transporterEmotional processingSerotonergic systemDiagnosis of major depressive disorderAnxiolytic effect of citalopramFacial emotion processing taskMonths of antidepressant treatmentViewing fearful facesAcute anxiolytic effectsEmotion processing taskEffect of citalopramReduced fMRI activationSuperior frontal sulcusSERT availabilityFearful facesHappy facesAntidepressant treatmentFear processingNeutral facesDepressive disorderConnecting the dots: approaching a standardized nomenclature for molecular connectivity in positron emission tomography
Reed M, Cocchi L, Sander C, Chen J, Matheson G, Fisher P, Volpi T, Khattar N, DeLorenzo C, Gryglewski G, Silberbauer L, Murgaš M, Godbersen G, Nics L, Walter M, Hacker M, Bertoldo A, Lubberink M, Silfstein M, Ogden R, Mann J, Suhara T, Varrone A, Boellaard R, Gunn R, Hammers A, Biswal B, Rosen B, Knudsen G, Carson R, Price J, Lanzenberger R, Hahn A. Connecting the dots: approaching a standardized nomenclature for molecular connectivity in positron emission tomography. European Journal Of Nuclear Medicine And Molecular Imaging 2025, 53: 48-58. PMID: 40455254, PMCID: PMC12660352, DOI: 10.1007/s00259-025-07357-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFunctional connectivityFMRI resting-state functional connectivityResting-state functional connectivityNeurobiological underpinningsMeasured PET signalBrain regionsConnectivity analysisPositron emission tomographyConnectivity metricsConnectivity studiesBetween-subjectsPET signalEmission tomographyBrainImaging modalitiesDiverse methodologiesMolecular connectivityMolecular covariatesFMRIPositronSimplified methods for SERT occupancy estimation measured with [11C]DASB PET bolus plus infusion
Ponce de León M, Murgaš M, Silberbauer L, Hacker M, Gryglewski G, Hahn A, Lanzenberger R. Simplified methods for SERT occupancy estimation measured with [11C]DASB PET bolus plus infusion. NeuroImage 2025, 311: 121208. PMID: 40221064, DOI: 10.1016/j.neuroimage.2025.121208.Peer-Reviewed Original ResearchSerotonin transporterBolus plus constant infusionSerotonin transporter occupancyDepressive disorderBinding potentialBolus plus infusionReference regionCitalopramHealthy controlsArterial blood samplesPET/MRI scansPET scansOccupational valuesIntravenous applicationConstant infusionBlood samplesIn vivoAntidepressantsInfusionSaline solutionSerotoninHighest agreementDisordersRadioligandPlacebo
2023
Impact of genetic variants within serotonin turnover enzymes on human cerebral monoamine oxidase A in vivo
Spies M, Murgaš M, Vraka C, Philippe C, Gryglewski G, Nics L, Balber T, Baldinger-Melich P, Hartmann A, Rujescu D, Hacker M, Winkler-Pjrek E, Winkler D, Lanzenberger R. Impact of genetic variants within serotonin turnover enzymes on human cerebral monoamine oxidase A in vivo. Translational Psychiatry 2023, 13: 208. PMID: 37322010, PMCID: PMC10272199, DOI: 10.1038/s41398-023-02506-2.Peer-Reviewed Original ResearchConceptsMAO-A levelsMAO-A VTSerotonin turnoverCerebral serotonin systemPositron emission tomography studyGenetic variantsEmission tomography studiesTryptophan hydroxylase 2 geneCerebral MAODepressed cohortBrain MAOMonoamine oxidase ASerotonin systemRelated clinical phenomenaRs1386494Distribution volumeTPH2 polymorphismsTomography studyClinical phenomenaMonoamine oxidase
2022
Meta-analysis of molecular imaging of translocator protein in major depression
Eggerstorfer B, Kim JH, Cumming P, Lanzenberger R, Gryglewski G. Meta-analysis of molecular imaging of translocator protein in major depression. Frontiers In Molecular Neuroscience 2022, 15: 981442. PMID: 36226319, PMCID: PMC9549359, DOI: 10.3389/fnmol.2022.981442.Peer-Reviewed Original ResearchBody mass indexMajor depressive disorderMDD patientsMolecular imaging studiesTranslocator proteinImaging studiesTSPO availabilityPositron emission tomography studyMarkers of neuroinflammationSerotonin transporter availabilityEmission tomography studiesSystematic literature searchTime of scanningEffect sizeMolecular neuroimaging studiesMass indexDepressive disorderHealthy controlsMajor depressionTransporter availabilityHealthy subjectsTreatment statusDepression severityTemporal cortexBrain regionsABCB1 variants and sex affect serotonin transporter occupancy in the brain
Silberbauer LR, Rischka L, Vraka C, Hartmann AM, Godbersen GM, Philippe C, Pacher D, Nics L, Klöbl M, Unterholzner J, Stimpfl T, Wadsak W, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R, Gryglewski G. ABCB1 variants and sex affect serotonin transporter occupancy in the brain. Molecular Psychiatry 2022, 27: 4502-4509. PMID: 36071112, PMCID: PMC7613909, DOI: 10.1038/s41380-022-01733-1.Peer-Reviewed Original ResearchConceptsMinor allele carriersTransporter occupancyAllele carriersABCB1 single nucleotide polymorphismsBasic clinical variablesCitalopram plasma concentrationsYears of ageMajor allele homozygotesCross-over designPET/MRISERT occupancyClinical variablesTreatment promisesClinical algorithmMajor depressionPlasma concentrationsPrecision pharmacotherapyABCB1 variantsHealthy volunteersABCB1 geneAllele homozygotesSame dosageDrug-target engagementTarget engagementSingle nucleotide polymorphismsBiodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1
Rischka L, Murgaš M, Pichler V, Vraka C, Rausch I, Winkler D, Nics L, Rasul S, Silberbauer LR, Reed MB, Godbersen GM, Unterholzner J, Handschuh P, Gryglewski G, Mindt T, Mitterhauser M, Hahn A, Ametamey SM, Wadsak W, Lanzenberger R, Hacker M. Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[11C]Me-NB1. EJNMMI Research 2022, 12: 53. PMID: 36018389, PMCID: PMC9418393, DOI: 10.1186/s13550-022-00925-8.Peer-Reviewed Original ResearchExtrasynaptic NMDA receptorsStandardized uptake valueNMDA receptorsUrinary bladderEffective dose coefficientsPET radioligandNeuropsychiatric disordersTreatment monitoringSynaptic NMDA receptorsTime-integrated activity coefficientsCentral nervous systemUrinary bladder contentsDrug developmentDose coefficientsAdverse eventsExcitotoxic processTRIAL REGISTRATIONBladder contentsHealthy subjectsSynaptic transmissionSide effectsBone marrowNervous systemUptake valueEffective dose